ADVANCE Post-Hoc Analysis: Triple Combination Reduces Total Mortality by 28 Percent

Clinical guidelines and specialized publications show that effective blood pressure management relies on dietary adjustments and multi-drug approaches, ad-hoc-news.de reported. Data from the Deutsche Hochdruckliga indicate that hypertension affects more than one-third of individuals aged 30 to 79 years. Drug monotherapy provides effective control in at most 30 percent of cases, increasing the reliance on combined regimens ad-hoc-news.dead-hoc-news.dead-hoc-news.deOpen source ↗.

Triple Combination and Clinical Outcomes

A post-hoc analysis of the ADVANCE study showed that a fixed triple combination of perindopril, indapamid, and amlodipine (in doses ranging from 5/1.25/5 mg to 10/2.5/10 mg) led to a 28 percent reduction in all-cause mortality. The same regimen demonstrated a 24 percent reduction in cardiovascular mortality. Additional reports indicated that this specific triple combination enabled 93 percent of treated patients to achieve readings below 130/80 mm Hg within three months.

Hypertension in middle age increases dementia risk by 61 percent, and 54 percent of all strokes are directly attributed to high blood pressure. Subclinical brain damage occurs in 44 percent of hypertensive patients over 65 years of age. Each additional drug class added to treatment reduces stroke risk by 23 percent, and maintaining an intensive target below 120 mm Hg slows the progression of white matter brain lesions more effectively than a threshold below 140 mm Hg.

Guideline Recommendations and Targets

The 2026 guidelines from the International Society of Hypertension (ISH), published in the Journal of Hypertension, define clinic readings of 130–139/80–89 mm Hg as elevated blood pressure. The optimal treatment target is established below 130/80 mm Hg for office, home, and daytime measurements, with essential care targeting values below 140/90 mm Hg ad-hoc-news.dead-hoc-news.dead-hoc-news.deOpen source ↗. For resistant hypertension, newer options include aprocitentan, esaxerenone, baxdrostat, lorundrostat, and zilebesiran, which remains active for at least six months. Interventional procedures such as renal denervation are restricted to specialized centers, provided estimated glomerular filtration rate is at least 40 milliliters per minute.